The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.
Stoke Therapeutics, a US-based genetic medicine developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, has filed for an initial public offering.
The company plans to float on the Nasdaq Global Select Market and has set a placeholder figure of $86m as a target.
Founded in 2014, Stoke is developing drugs designed to treat serious conditions caused by gene function being lost or diminished.
The IPO proceeds will fund a phase 3 clinical trial of…
